Cytek Biosciences (CTKB) Receivables (2020 - 2026)

Cytek Biosciences' Receivables history runs 7 years deep, the most recent figure standing at $54.1 million for Q1 2026.

• Quarterly Receivables fell 4.62% year-over-year to $54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.1 million (down 4.62% YoY) and the FY2025 annual result came in at $65.0 million, up 4.35% from the prior year.
• Receivables was $54.1 million for Q1 2026 at Cytek Biosciences, down from $65.0 million in the prior quarter.
• Across five years, Receivables topped out at $65.0 million in Q4 2025 and bottomed at $38.9 million in Q2 2022.
• A 5-year average of $53.1 million and a median of $54.1 million in 2026 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 63.43% — and 2024, when it slipped 8.53%.
• Cytek Biosciences' Receivables stood at $51.0 million in 2022, then advanced by 14.62% to $58.5 million in 2023, then advanced by 6.5% to $62.3 million in 2024, then gained by 4.35% to $65.0 million in 2025, then slipped by 16.76% to $54.1 million in 2026.
• Business Quant data shows CTKB's Receivables at $54.1 million in Q1 2026, $65.0 million in Q4 2025, and $58.8 million in Q3 2025.